
Nephrology Asst Professor @ECUHealth_IM I Transplant Nephrology @OHSUNephrology I
Joined November 2021
- Tweets72
- Following747
- Followers235
- Likes104
Debargha Basuli, MD PhD retweeted
SGLT2 inhibitors in hemodialysis or peritoneal dialysis patients: rationale and state-of-the art
doi.org/10.1093/ckj/sfaf350
Debargha Basuli, MD PhD retweeted
Confession: I LOVE hyponatremia 🤓
(I know, I know. What can I say, I'm a true internist!)
HypoNa is often feared, maligned, and misunderstood - but I promise it doesn't have to be scary!
Here are my top 10 hyponatremia tips and tricks - a 🧵
Debargha Basuli, MD PhD retweeted
Fluid overload occurs frequently in critically ill patients with AKI and is one of the indications for continuous kidney replacement therapy (CKRT). In this article, the authors state that available and emerging tools help predict and monitor volume status more actively and dynamically to best design UF strategies that avoid hypotension but alleviate congestion. bit.ly/CJASN0650
@GonzaRGuerrero
Debargha Basuli, MD PhD retweeted
KIDNEYcon Registration is Open!
April 6-8, 2024
Little Rock, AR
kidneycon.org/registration
Little Rock will experience the 2024 Total Solar Eclipse
Discount room rates at the DoubleTree Hotel!
@NephroRock @nephrosharma @nephrosingh @VelezNephHepato @kidney_boy
Debargha Basuli, MD PhD retweeted
Re-reading excellent thread by
@NephroMD. In Winzeler paper, UOsm>=500 is highly specific for non-responsiveness but v. insensitive
🤔How about:
UOsm>500: don't bother with FR
UOsm<300: FR should be first-line approach
300-500: Consider trial of FR
❓
This Post is from an account that no longer exists. Learn more
Debargha Basuli, MD PhD retweeted
DARE-ESKD 1: Pharmacokinetic Properties of SGLT2 inhibitor (SGLT2i) Dapagliflozin in Patients on Hemodialysis and Peritoneal Dialysis ca. 2023 from @CJASN #Nephpearls
- Well tolerated
- Slightly dialyzable
- Non-accumulating pharmacokinetic properties
pubmed.ncbi.nlm.nih.gov/3722… – at Riverside, IL
Debargha Basuli, MD PhD retweeted
Looks like you can #Flozinate your dialysis patients!
"In individuals with kidney failure on dialysis, dapagliflozin was well-tolerated, slightly dialyzable, and had non-accumulating pharmacokinetic properties"
journals.lww.com/cjasn/_layo…
Debargha Basuli, MD PhD retweeted
✅IT OUT 👇
📢📢📢Tweetorial Alert (1/19)!
What is the most common complication of routine outpatient hemodialysis (HD) treatments?
15%Infection
2%Thrombosis
64%Hypotension
19%Anemia
527 votes • Final results Debargha Basuli, MD PhD retweeted
Genomics in Glomerular Disease
A GlomCon Pubs summary on genetic diagnoses of glomerular diseases by Dr. Benjamin Tan @NephBen
Read more 👉🏻 pubs.glomcon.org/genomics-in…
#GlomCon
Debargha Basuli, MD PhD retweeted
Our article in @NatRevImmunol proposes that nephritis can be classified primarily according to cause, then by the lesion. This would improve management, education, understanding and research.
Thanks to @hjanders_hans @PRomagnani and Prof Nelson Leung for a great collaboration.
Glomerulonephritis: immunopathogenesis and immunotherapy dlvr.it/Sgmj79
Debargha Basuli, MD PhD retweeted
A nice refresher of high yield kidney disorders!
#TBThursday
-md
renalfellow.org/2020/05/21/h…
Debargha Basuli, MD PhD retweeted
Ambulatory Hemodialysis Unit Rounds:
Called to see a patient with hypotension: BP 76/40,🧠 OK, CRT 5 seconds
1st step ➡️🛑Ultrafiltration + 300 ml bolus. BP 90/60
Pt is a middle aged ♂️ w ESRD and T2DM
1/9 🧵
Debargha Basuli, MD PhD retweeted
📌 A very comprehensive stepwise ECG algorithm
👉 to predict site of origin of idiopathic VAs
#ECG #CardioTwitter #EPeeps @adribaran @ECGTalk @DrFerminGarcia @DrJasonAndrade @DhirajGuptaBHRS @SeguraCardio @jvillacastin @smithECGBlog @AskDrShashank @ecgrhythms @iamritu @Hragy
Debargha Basuli, MD PhD retweeted
#AKIConsultSeries:👨w T2DM➡️🏥 for fever, dysuria and CVA tenderness. On arrival: ⬇️BP, ⬆️Glucose, ⬆️AGMA. Dx UTI + DKA. Tx: Abx + Insulin Pump + 4 L Crystalloid + NE
After resus, pt still oliguric, Cr 3.2. NE 0.7 ug/kg/min,🧠confused, BP 85/62, HR 123, 2L O2. CRT 4 sec
1/12
Debargha Basuli, MD PhD retweeted
1) Welcome to this new #accredited #tweetorial on best practices for providing #interprofessional, multidisciplinary, and multimodal pharmacologic therapy for patients with #CKD-associated anemia #aCKD. #MedTwitter #FOAMed #nephtwitter @MedTweetorials
Debargha Basuli, MD PhD retweeted
sacubitril...any data in ESRD?
#AskRenal
Debargha Basuli, MD PhD retweeted
1) Welcome to a new #accredited #tweetorial on the latest advances in the management of #CKD in the setting of patients with and without #T2D--this time with a hot-off-the-presses update from #ASN22 #KIDNEYWEEK2022: eagerly-awaited results of the #EMPA_KIDNEY trial.
Debargha Basuli, MD PhD retweeted
KDIGO is pleased to announce the publication of the 2022 Diabetes Management in CKD Guideline.
Read the Guideline:
kdigo.co/2022-Diabetes-in-CK…
Read the Executive Summary:
kdigo.co/2022-Diabetes-Guide…
Read the News Release:
kdigo.co/News-Release-2022-D…
#diabetes #CKD








































